{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Avidity+Biosciences%2C+Inc.", "query": { "sponsor": "Avidity Biosciences, Inc." }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Avidity+Biosciences%2C+Inc.&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T01:16:38.365Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06547216", "title": "Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "FSHD", "FSHD1", "FSHD2", "FMD", "FMD2", "Fascioscapulohumeral Muscular Dystrophy", "Fascioscapulohumeral Muscular Dystrophy Type 1", "Fascioscapulohumeral Muscular Dystrophy Type 2", "Dystrophies, Facioscapulohumeral Muscular", "Dystrophy, Facioscapulohumeral Muscular", "Facioscapulohumeral Muscular Dystrophy 1", "Facioscapulohumeral Muscular Dystrophy 2", "Facio-Scapulo-Humeral Dystrophy", "Atrophy, Facioscapulohumeral", "Atrophies, Facioscapulohumeral", "Facioscapulohumeral Atrophy", "Muscular Dystrophies", "Muscular Dystrophy, Facioscapulohumeral", "FSH Muscular Dystrophy", "Landouzy Dejerine Dystrophy", "Landouzy-Dejerine Muscular Dystrophy", "Dystrophies, Landouzy-Dejerine", "Dystrophy, Landouzy-Dejerine", "Landouzy-Dejerine Syndrome", "Muscular Dystrophy, Landouzy Dejerine", "Progressive Muscular Dystrophy", "FSH" ], "interventions": [ { "name": "AOC 1020", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "16 Years to 72 Years" }, "enrollment_count": 84, "start_date": "2024-07-25", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06547216" }, { "nct_id": "NCT05670730", "title": "Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy", "Exon 44" ], "interventions": [ { "name": "AOC 1044", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "7 Years to 55 Years · Male only" }, "enrollment_count": 70, "start_date": "2022-11-09", "completion_date": "2024-11-25", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05670730" }, { "nct_id": "NCT05747924", "title": "Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "FSHD", "FSHD1", "FSHD2", "FMD", "FMD2", "Fascioscapulohumeral Muscular Dystrophy", "Fascioscapulohumeral Muscular Dystrophy Type 1", "Fascioscapulohumeral Muscular Dystrophy Type 2", "Dystrophies, Facioscapulohumeral Muscular", "Dystrophy, Facioscapulohumeral Muscular", "Facioscapulohumeral Muscular Dystrophy 1", "Facioscapulohumeral Muscular Dystrophy 2", "Facio-Scapulo-Humeral Dystrophy", "Atrophy, Facioscapulohumeral", "Atrophies, Facioscapulohumeral", "Facioscapulohumeral Atrophy", "Muscular Dystrophies", "Muscular Dystrophy, Facioscapulohumeral", "FSH Muscular Dystrophy", "Landouzy Dejerine Dystrophy", "Landouzy-Dejerine Muscular Dystrophy", "Dystrophies, Landouzy-Dejerine", "Dystrophy, Landouzy-Dejerine", "Landouzy-Dejerine Syndrome", "Muscular Dystrophy, Landouzy Dejerine", "Progressive Muscular Dystrophy", "FSH" ], "interventions": [ { "name": "AOC 1020", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2023-04-04", "completion_date": "2026-03-20", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05747924" }, { "nct_id": "NCT04635891", "title": "Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "FSHD" ], "interventions": [], "intervention_types": [], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 450, "start_date": "2020-12-15", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 16, "location_summary": "Los Angeles, California • Stanford, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04635891" }, { "nct_id": "NCT05479981", "title": "Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DM1", "Muscular Dystrophies", "Myotonic Dystrophy", "Myotonic Dystrophy 1", "Myotonic Disorders", "Muscular Disorders, Atrophic", "Muscular Diseases", "Musculoskeletal Diseases", "Neuromuscular Diseases", "Nervous System Diseases", "Genetic Diseases, Inborn", "Heredodegenerative Disorders, Nervous System", "Neurodegenerative Diseases" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "AOC 1001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 37, "start_date": "2022-08-04", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 8, "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479981" }, { "nct_id": "NCT07008469", "title": "Global Open-Label Extension Study of Del-desiran for the Treatment of DM1", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myotonic Dystrophy Type 1", "DM1", "Myotonic Dystrophy", "Myotonia", "Myotonic Dystrophy 1", "Myotonic Disorders", "Steinert Myotonic Dystrophy", "Steinert Disease" ], "interventions": [ { "name": "Del-desiran (AOC 1001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 199, "start_date": "2025-06-26", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 19, "location_summary": "Los Angeles, California • Stanford, California • Denver, Colorado + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07008469" }, { "nct_id": "NCT06244082", "title": "Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DMD", "Duchenne Muscular Dystrophy", "Duchenne", "Exon 44" ], "interventions": [ { "name": "AOC 1044", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "27 Years", "sex": "MALE", "summary": "7 Years to 27 Years · Male only" }, "enrollment_count": 39, "start_date": "2024-01-22", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • La Jolla, California • Sacramento, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Carlos", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06244082" }, { "nct_id": "NCT07038200", "title": "A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Facioscapulohumeral Muscular Dystrophy", "FSHD", "FSHD - Facioscapulohumeral Muscular Dystrophy", "FSHD1", "FSHD2", "Fascioscapulohumeral Muscular Dystrophy", "Fascioscapulohumeral Muscular Dystrophy Type 1", "Fascioscapulohumeral Muscular Dystrophy Type 2", "Facioscapulohumeral Muscular Dystrophy 1", "Facioscapulohumeral Dystrophy", "Facio-Scapulo-Humeral Dystrophy", "Facioscapulohumeral Muscular Dystrophy 2", "Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)", "FSH Muscular Dystrophy", "Landouzy Dejerine Dystrophy", "Landouzy-Dejerine Muscular Dystrophy", "Landouzy-Dejerine Syndrome" ], "interventions": [ { "name": "AOC-1020", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "16 Years to 70 Years" }, "enrollment_count": 200, "start_date": "2025-06-10", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 14, "location_summary": "Orange, California • Palo Alto, California • Denver, Colorado + 11 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07038200" }, { "nct_id": "NCT05027269", "title": "Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "DM1", "Myotonic Dystrophy 1", "Myotonic Dystrophy", "Myotonic Dystrophy Type 1 (DM1)", "Dystrophy Myotonic", "Myotonic Disorders", "Steinert Disease", "Myotonic Muscular Dystrophy" ], "interventions": [ { "name": "AOC 1001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 39, "start_date": "2021-10-28", "completion_date": "2023-02-14", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 8, "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027269" }, { "nct_id": "NCT07250737", "title": "Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Muscular Disorders, Atrophic", "Muscular Diseases", "Musculoskeletal Diseases", "Neuromuscular Diseases", "Nervous System Diseases", "Genetic Diseases, Inborn", "Genetic Diseases, X-Linked", "Muscular Dystrophies", "Muscular Dystrophy, Duchenne" ], "interventions": [ { "name": "delpacibart zotadirsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avidity Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "MALE", "summary": "2 Years and older · Male only" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-04T01:16:38.365Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "San Carlos", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07250737" } ] }